Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry

Yu-Wei Chen¹,², Chen-Hua Li¹,², Chih-Dong Yang³, Chung-Hsiang Liu⁴, Chih-Hung Chen⁵, Jau-Jian Sheu⁶, Shinn-Kuang Lin⁷, An-Chih Chen⁸, Ping-Kun Chen⁹, Po-Lin Chen¹⁰, Chung-Hsin Yeh¹¹,¹²,¹³, Jinn-Rong Chen¹⁴, Yu-Jen Hsiao¹⁵, Ching-Huang Lin¹⁶, Shih-Pin Hsu¹⁷, Tsang-Shan Chen¹⁸, Sheng-Feng Sung¹⁹, Shih-Chieh Yu²⁰, Chih-Hsin Muo²¹, Chi Pang Wen²²,²³, Fung-Chang Sung²⁴*, Jiann-Shing Jeng¹,²⁴*, Chung Y. Hsu²⁵, Taiwan Stroke Registry Investigators²⁶

¹ Department of Neurology, Taiwan Landseed Hospital, Taoyuan, Taiwan, ² Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan, ³ Department of Neurosurgery, Taiwan Landseed Hospital, Taoyuan, Taiwan, ⁴ Department of Neurology, China Medical University Hospital, Taichung, Taiwan, ⁵ Department of Neurology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, ⁶ Department of Neurology, Taipei Medical University Hospital, Taipei, Taiwan, ⁷ Department of Neurology, Taipei Tzu Chi Hospital, and School of Medicine, Tzu Chi University, Hualien, Taiwan, ⁸ Department of Neurology, Chung Shan Medical University Hospital, Taichung, Taiwan, ⁹ Department of Neurology, Lin Shin Hospital, Taichung, Taiwan, ¹⁰ Department of Neurology, Taichung Veterans General Hospital, Taichung, Taiwan, ¹¹ Department of Neurology, Yuan Rung Hospital, Changhua, Taiwan, ¹² Department of Sport and Health Management, Da-Yeh University, Changhua, Taiwan, ¹³ Department of Nursing, College of Medicine & Nursing, Hung-Kuang University, Taichung, Taiwan, ¹⁴ Department of Neurology, Yunlin Christian Hospital, Yunlin, Taiwan, ¹⁵ Department of Neurology, National Taiwan University Hospital—Yunlin Branch, Yunlin, Taiwan, ¹⁶ Department of Neurology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ¹⁷ Department of Neurology, E-Da Hospital, Kaohsiung, Taiwan, ¹⁸ Department of Neurology, Sin-Lau Hospital, Tainan, Taiwan, ¹⁹ Division of Neurology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan, ²⁰ Department of Neurology, Kuang Tien General Hospital, Taichung, Taiwan, ²¹ Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, ²² National Health Research Institutes, Miaoli, Taiwan, ²³ Department of Health Services Administration, China Medical University, Taichung, Taiwan, ²⁴ Stroke Center, National Taiwan University Hospital, Taipei, Taiwan, ²⁵ Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan

¶ Membership of the Taiwan Stroke Registry Investigators is given in the Acknowledgments.
* jsjeng@ntu.edu.tw (JSJ); fcsung1008@yahoo.com.tw (FCS)

Abstract

The relationship between cholesterol level and hemorrhagic stroke is inconclusive. We hypothesized that low cholesterol levels may have association with intracerebral hemorrhage (ICH) severity at admission and 3-month outcomes. This study used data obtained from a multi-center stroke registry program in Taiwan. We categorized acute spontaneous ICH patients, based on their baseline levels of total cholesterol (TC) measured at admission, into 3 groups with <160, 160–200 and >200 mg/dL of TC. We evaluated risk of having initial stroke severity, with National Institutes of Health Stroke Scale (NIHSS) >15 and unfavorable outcomes (modified Rankin Scale [mRS] score >2, 3-month mortality) after ICH by the TC group. A total of 2444 ICH patients (mean age 62.5±14.2 years; 64.2% men) were included in this study and 854 (34.9%) of them had baseline TC <160 mg/dL. Patients with TC <160
mg/dL presented more often severe neurological deficit (NIHSS >15), with an adjusted odds ratio [aOR] of 1.80; 95% confidence interval [CI], 1.41–2.30), and 3-month mRS >2 (aOR, 1.41; 95% CI, 1.11–1.78) using patients with TC >200 mg/dL as reference. Those with TC >160 mg/dL and body mass index (BMI) <22 kg/m² had higher risk of 3-month mortality (aOR 3.94, 95% CI 1.76–8.80). Prior use of lipid-lowering drugs (2.8% of the ICH population) was not associated with initial severity and 3-month outcomes. A total cholesterol level lower than 160 mg/dL was common in patients with acute ICH and was associated with greater neurological severity on presentation and poor 3-month outcomes, especially with lower BMI.

Introduction

Hypercholesterolemia is associated with increased risks of coronary artery events, coronary revascularization and ischemic stroke. Reduction of low-density lipoprotein cholesterol (LDL-C) with lipid-lowering agents has been demonstrated to significantly reduce the cardiovascular risks [1]. However, the relationship between cholesterol levels and stroke seems less evident than the relationship between the extent of reduction of LDL-C and cardiovascular events. Previous epidemiologic studies showed that hypercholesterolemia was associated with a lower risk of intracerebral hemorrhage (ICH) [2], while the low LDL-C level increased the risk of ICH mortality [3, 4]. A recent systematic review and meta-analysis reported an inverse relationship between total cholesterol (TC) levels and the risk of hemorrhagic stroke [5]. However, there were conflicting study findings on the association between lipid-lowering medications and the risk of ICH [6, 7]. A meta-analysis of randomized controlled trials showed that statins, the medication of choice for hypercholesteremia, may reduce the overall incidence of stroke [8], but conflicting results were also found in the impact of prior use of statins on the prognosis of ICH; it could be neutral [4], favorable with reduced mortality [9], or even worse [10]. The relationship between TC and ICH risk has not been well studied yet for the Asian population, which may be different from Western populations. Therefore, this study used a multi-center stroke registry to investigate the relationship between serum cholesterol level and the severity and prognosis of acute ICH, and functional outcome and deaths at 3 month after stroke.

Methods

Patients

The Taiwan Stroke Registry (TSR) is a nationwide prospective registry with 39 participating stroke centers. The details of diagnosis, inclusion criteria and collection of variables of this program has been presented elsewhere [11]. In brief, patients with an acute cerebrovascular event were prospectively enrolled in the registry within 10 days of admission or during hospitalization and followed up prospectively. An expert panel established a consensus protocol on data collection criteria, including demographic data, related medications, etiological factors, clinical course, prognosis, complications of the index cerebrovascular events. Diagnosis and stroke subtypes were determined based on clinical features and laboratory examinations, brain imaging, echocardiography, vascular ultrasonography and angiography. All patients with non-traumatic ICH were referred to neurologists or neurosurgeons for confirmation of the diagnosis. Patients with ICH secondary to acute cerebral infarct were excluded from the data analysis. Stroke patients were scheduled to follow-up checkups at 1, 3, 6 and 12 months after stroke.
onset. The Taiwan Stroke Registry was approved by "Research Ethics Committee, China Medical University and Hospital, Taichung, Taiwan" and every Institutional Review Board of each stroke center approved the participation in the registry program. Written informed consent for participation in the registry program was obtained from each patient or his/her legal representatives with the approval of attending physician. A numeric code was assigned to each patient whose clinical data in the registry containing no individual identification numbers or any privacy data. The whole data set, a big database, has been approved for big data analytics for research topics such as the one in this study.

More than 40,000 stroke patients were registered from 1st May 2006 to 30th April 2009. Patients without data of fasting TC during hospitalization were excluded from this study. Patients were categorized into three groups based on the baseline levels: <160, 160–200, and >200 mg/dL of TC. The cut-off points of 160 and 200 mg/dL were adopted from the Framingham Heart Study [12] and Adult Treatment Panel (ATP) III classification [13]. Both National Institute of Health Stroke Scale (NIHSS) and Glasgow Coma Scale (GCS) were recorded at the emergent room or at the admission to assess the initial severity of stroke. The baseline scores of NIHSS were stratified by the cut points of 14 and 24 [14] and GCS were stratified by the cut points of 4 and 12. Patients with a NIHSS >15 were defined as severe and very severe stroke cases [15]. Modified Rankin Scales (mRS) and deaths identified within 3 months after stroke were used to assess functional outcomes and the risk of mortality. The vascular risk factors were defined to conform to the consensus of TSR criteria [11]. The functional outcome and vital status of all patients were determined by examining medical records and/or telephone interviews.

Statistical analysis

Data analysis first compared distributions of sex, mean age, mean body mass index, risk factors of stroke, medication history and laboratory data among three TC groups (levels of <160, 160–200 and >200 mg/dL). We used χ² test to examine the distribution of each categorical variable among these TC groups and used Kruskall-Wallis test to examine differences among means, using a significance level of 0.05. Because the baseline characteristics of ICH patients in three groups may confound the outcome of interests, we further selected the study subjects with the propensity score matching method to determine if there was significant difference of clinical characteristics among the three groups.

We stratified TC into 11 levels to determine the relationship between mean initial NIHSS scores and TC, which was in a 20 mg/dL increment of TC, from <100, 100–119, and through >280 mg/dL. Univariate and multivariate logistic regression analyses were used to determine crude odds ratios (OR) and adjusted odds ratios (aOR), respectively, and 95% confidence intervals (CI) of initial NIHSS score >15, of 3-month mRS >2 and of 3-month mortality in association with TC using patients with TC >200 mg/dL as the reference group. Further data analysis evaluated the joint effect of TC (<160 vs. ≥160 mg/dL) and body mass index (<22.0, 22.0–26.9 and ≥27.0 kg/m²) on the outcomes of interest. The multivariate analysis first included only sex and age for adjustment. Further analysis included variables significant at p <0.05 in the univariate analysis and variables with biological plausibility. We used the SAS statistical package (version 9.1; SAS Institute, Cary, NC, USA) to perform data analysis.

Results

A total of 2444 spontaneous ICH patients with baseline fasting TC levels measured immediately after stroke were included in this study after excluding 4139 patients without fasting TC records from the TSR (Fig 1). Of these patients (mean age, 62.5±14.2 years; men, 64.2%),
13.7% had previous ischemic stroke or transient ischemic attack and 7.8% had a history of ICH (Table 1). The average time from symptom onset to hospital arrival was 5.3 ± 7.8 hours. Patients on admission presented with a median GCS score of 15 (interquartile range [IQR], 11–15) and a median NIHSS score of 9 (IQR, 4–18). The site of ICH occurred most frequently at the putamen (31.6%), followed by the thalamus (19.2%), lobes (12.8%), pons (6.8%), cerebellum (6.7%), and intraventricular hemorrhage (2.2%). Sixteen percent of patients had ICH at more than one site. During hospitalization, 14.6% of them had received hematoma evacuation or ventricular drainage surgery. The overall case-fatality rate of ICH at discharge was 4.9% and at 3-month was 8.2%. The median mRS at discharge was 4 (IQR, 2–5), with 48.8% of patients had a mRS of >2.

Table 1 shows that about one third (854, 34.9%) of patients had a baseline fasting TC < 160 mg/dL and about one fourth (648, 26.5%) had TC > 200 mg/dL. Patients with TC < 160 mg/dL were older and mainly male, and had a lower BMI. These patients were also more prevalent with previous ischemic stroke and transient ischemic attack, atrial fibrillation, end-stage renal disease and smoking, but less prevalent with hypertension. There was a positive association between TC levels and blood pressures, hematocrit and platelet counts, but a reverse association between TC levels and creatinine levels. The neurological presentation in Table 1 also shows that patients with TC < 160 mg/dL had higher NIHSS and lower GCS scores, were more likely to receive surgery for ICH, and had a higher rate of mRS > 2 and a higher 3-month mortality.

Fig 2 shows that the mean NIHSS score decreased from 20 points for patients with a TC < 100 mg/dL to 11 points for those with a TC ≥ 280 mg/dL (Pearson correlation coefficient = -0.74, **P** < 0.001).
Table 1. Characteristics of patients with intracerebral hemorrhage by the levels of initial total cholesterol.

| Characteristic                              | All patients (n = 2444) | Total cholesterol levels | P value |
|---------------------------------------------|-------------------------|--------------------------|---------|
| Age, y                                      | 62.5±14.2               | < 160 mg/dL (n = 854) | 160–200 mg/dL (n = 942) | > 200 mg/dL (n = 648) |
| Male                                        | 1570 (64.2)             |                          |                     |                     |
| Body mass index, kg/m²                       | 24.7±4.3                |                          |                     |                     |
| Medical history                             |                         |                          |                     |                     |
| Hypertension                                | 2102 (86.6)             |                          |                     |                     |
| Diabetes mellitus                           | 619 (25.6)              |                          |                     |                     |
| Previous ischemic stroke / TIA              | 334 (13.7)              |                          |                     |                     |
| Previous ICH                                | 187 (7.8)               |                          |                     |                     |
| Atrial fibrillation                         | 116 (4.8)               |                          |                     |                     |
| ESRD                                        | 84 (3.5)                |                          |                     |                     |
| Smoking                                     | 898 (37.1)              |                          |                     |                     |
| Medical history                             |                         |                          |                     |                     |
| Hypertension                                | 2102 (86.6)             |                          |                     |                     |
| Diabetes mellitus                           | 619 (25.6)              |                          |                     |                     |
| Previous ischemic stroke / TIA              | 334 (13.7)              |                          |                     |                     |
| Previous ICH                                | 187 (7.8)               |                          |                     |                     |
| Atrial fibrillation                         | 116 (4.8)               |                          |                     |                     |
| ESRD                                        | 84 (3.5)                |                          |                     |                     |
| Smoking                                     | 898 (37.1)              |                          |                     |                     |
| Pre-I CH medications                        |                         |                          |                     |                     |
| Lipid-lowering drugs                        | 68 (2.8)                |                          |                     |                     |
| Antiplatelets                               | 200 (8.2)               |                          |                     |                     |
| Anticoagulants                              | 43 (1.8)                |                          |                     |                     |
| Anti-hypertensive drugs                     | 971 (39.7)              |                          |                     |                     |
| Anti-diabetic drugs                         | 321 (13.1)              |                          |                     |                     |
| Laboratory data                             |                         |                          |                     |                     |
| Systolic blood pressure, mmHg               | 178.2±36.2              |                          |                     |                     |
| Diastolic blood pressure, mmHg              | 100.8±23.3              |                          |                     |                     |
| Hematocrit, %                               | 40.8±5.9                |                          |                     |                     |
| White blood cell count, cumm                | 9.5±9.7                 |                          |                     |                     |
| Platelet count, cumm                        | 209.1±79.6              |                          |                     |                     |
| Creatine, mg/dL                             | 1.4±1.6                 |                          |                     |                     |
| Sugar, mg/dL                                | 152.3±68.8              |                          |                     |                     |
| International normalized ratio              | 1.3±1.5                 |                          |                     |                     |
| NIHSS score on admission                    |                         |                          |                     |                     |
| 0–14                                        | 1592 (69.1)             |                          |                     |                     |
| 15–24                                       | 360 (15.6)              |                          |                     |                     |
| ≥25                                         | 352 (15.3)              |                          |                     |                     |
| Median (IQR)                                | 9 (4–18)                |                          |                     |                     |
| Initial GCS                                 | 98 (4.1)                |                          |                     |                     |
| 3–4                                         | 52 (6.2)                |                          |                     |                     |
| 5–12                                        | 292 (35.0)              |                          |                     |                     |
| ≥13                                         | 491 (58.8)              |                          |                     |                     |
| Median (IQR)                                | 15 (11–15)              |                          |                     |                     |
| Hematoma enlargement                        | 120 (4.9)               |                          |                     |                     |
| Surgery for ICH                             | 356 (14.6)              |                          |                     |                     |
| Stroke-in-evolution                          | 92 (3.8)                |                          |                     |                     |
| Infratentorial ICH                           | 194 (7.9)               |                          |                     |                     |
| Outcome at 3 months                         | 200 (8.2)               |                          |                     |                     |

(Continued)
Compared to patients with TC > 200 mg/dL, those with TC < 160 mg/dL had higher frequency of initial NIHSS > 15 (aOR, 1.80; 95% CI, 1.41–2.30) (Table 2). The corresponding adjusted ORs of 3-month mRS > 2 and 3-month mortality were 1.41 (95% CI, 1.11–1.78) and 2.19 (95% CI, 1.44–3.33). Fig 3 shows that the 3-month survival for patients with TC < 160 mg/dL was significantly lower than those with TC 160–200 mg/dL and > 200 mg/dL (86.3% vs. 93.4% and 96.9%, P < 0.001 by log-rank test). By the propensity score matching method, there was still significantly inverse association between initial NIHSS and TC levels, but the association of 3-month outcome and TC levels was borderline.

Table 3 shows that the estimated risks of NIHSS > 15 points were higher for patients with TC < 160 mg/dL in any BMI category using TC > 160 mg/dL and BMI > 27.0 kg/m² as the reference. The estimated risks of 3-month mRS > 2 and 3-month mortality were higher in patients with TC < 160 mg/dL and BMI < 22 kg/m² or 22.0–26.9 kg/m². In the groups of TC >
160 mg/dL, BMI <22.0 kg/m² had significantly higher risks of initial NIHSS >15, 3-month mRS >2 and mortality, with aORs of 1.81 (95% CI, 1.31–2.52), 1.53 (95% CI, 1.14–2.07) and 3.94 (95% CI, 1.76–8.80), respectively. Patients with both TC <160 mg/dL and BMI <22.0 kg/m² had an aOR of 3-month mortality of 4.11 (95% CI, 1.71–9.86). Among the groups with BMI >27.0 kg/m², those with TC <160 mg/dL had a significant higher aOR of initial NIHSS score >15 (2.09; 95% CI 1.33–3.30).

Table 2. Association between initial stroke severity and three month outcome by total cholesterol levels and pre-ICH lipid-lowering drugs use.

|                                | Odds ratio (95% confidence intervals) |
|--------------------------------|--------------------------------------|
|                                | Crude | Age/sex-adjusted | Multivariate adjusted§ |
| **All ICH patients (n = 2444)** |       |                  |                         |
| **Initial NIHSS score >15**     |       |                  |                         |
| Total cholesterol >200 mg/dL    | 1.00  | 1.00             | 1.00                    |
| 160–200 mg/dL                  | 1.02 (0.80–1.28) | 1.01 (0.80–1.29) | 1.03 (0.81–1.32)        |
| <160 mg/dL                     | 1.91 (1.52–2.40)‡ | 1.92 (1.52–2.44)‡ | 1.80 (1.41–2.30)‡        |
| Pre-ICH lipid-lowering drugs use | 0.74 (0.42–1.31) | 0.74 (0.42–1.31) | 0.67 (0.37–1.21)         |
| **3-month mRS >2**             |       |                  |                         |
| Total cholesterol >200 mg/dL    | 1.00  | 1.00             | 1.00                    |
| 160–200 mg/dL                  | 1.18 (0.95–1.46) | 1.09 (0.87–1.35) | 1.10 (0.88–1.38)        |
| <160 mg/dL                     | 1.66 (1.34–2.07)‡ | 1.45 (1.16–1.82)† | 1.41 (1.11–1.78)†        |
| Pre-ICH lipid-lowering drugs use | 0.72 (0.43–1.21) | 0.72 (0.43–1.22) | 0.59 (0.34–1.02)         |
| **3-month mortality**          |       |                  |                         |
| Total cholesterol >200 mg/dL    | 1.00  | 1.00             | 1.00                    |
| 160–200 mg/dL                  | 1.30 (0.85–1.99) | 1.23 (0.81–1.89) | 1.27 (0.81–1.97)        |
| <160 mg/dL                     | 2.69 (1.82–4.00)‡ | 2.40 (1.60–3.60)‡ | 2.19 (1.44–3.33)‡        |
| Pre-ICH lipid-lowering drugs use | 0.90 (0.37–2.19) | 0.92 (0.38–2.23) | 0.80 (0.33–1.97)         |
| **Selected ICH patients by Propensity Score Matching Method (n = 747)** |       |                  |                         |
| **Initial NIHSS score >15**     |       |                  |                         |
| Total cholesterol >200 mg/dL    | 1.00  | 1.00             | 1.00                    |
| 160–200 mg/dL                  | 0.97 (0.64–1.47) | 0.97 (0.64–1.47) | 0.87 (0.56–1.37)        |
| <160 mg/dL                     | 1.62 (1.09–2.40)† | 1.62 (1.09–2.40)† | 1.70 (1.11–2.60)†        |
| Pre-ICH lipid-lowering drugs use | 1.50 (0.65–3.48) | 1.49 (0.64–3.48) | 1.52 (0.56–4.11)         |
| **3-month mRS >2**             |       |                  |                         |
| Total cholesterol >200 mg/dL    | 1.00  | 1.00             | 1.00                    |
| 160–200 mg/dL                  | 1.28 (0.99–1.84) | 1.26 (0.87–1.85) | 1.26 (0.84–1.88)        |
| <160 mg/dL                     | 1.28 (1.88–1.84)‡ | 1.30 (0.89–1.89) | 1.37 (0.92–2.04)        |
| Pre-ICH lipid-lowering drugs use | 0.81 (0.35–1.87) | 0.76 (0.32–1.81) | 0.65 (0.24–1.73)         |
| **3-month mortality**          |       |                  |                         |
| Total cholesterol >200 mg/dL    | 1.00  | 1.00             | 1.00                    |
| 160–200 mg/dL                  | 1.97 (0.90–4.34) | 1.93 (0.87–4.25) | 1.79 (0.74–4.33)        |
| <160 mg/dL                     | 2.09 (0.96–4.56) | 2.01 (0.92–4.41) | 2.23 (0.94–5.31)        |
| Pre-ICH lipid-lowering drugs use | 2.87 (0.94–8.70) | 2.90 (0.94–8.93) | 1.53 (0.35–6.80)         |

*, indicating *P*<0.05
†, *P*<0.001
‡, *P*<0.0001.
§, model adjusted for age, gender, all medical history, pre-ICH medications and laboratory data.

https://doi.org/10.1371/journal.pone.0171379.t002
Discussion

The proportion of spontaneous ICH was 16.1% in all stroke patients registered in the TSR [11], similar to those in Western stroke populations (10–15%) [16] and Japanese population

Table 3. Odds ratios (95% confidence intervals) of three month outcome by total cholesterol levels and body mass index.

| Table 3. Odds ratios (95% confidence intervals) of three month outcome by total cholesterol levels and body mass index. | Total CHO <160 mg/dL | Total CHO >160 mg/dL |
|---|---|---|
| | BMI (kg/m²) | | BMI (kg/m²) | |
| Initial NIHSS score >15 | <22.0 | 22.0–26.9 | >27.0 |
| 3-month mRS >2 | 2.52 (1.80–3.51)† | 1.31 (0.93–1.84)‡ | 1.51 (0.99–2.31) |
| 3-month mortality | 4.11 (1.71–9.86)* | 2.77 (1.12–6.85)* | 2.46 (0.89–6.84) |

*, indicating $P<0.05$
†, $P<0.001$
‡, $P<0.0001$.

BMI, body mass index.

Model adjusted for age, gender, hypertension, diabetes mellitus, previous stroke, atrial fibrillation, end-stage renal disease, smoking and pre-ICH lipid-lowering drugs use.

All interaction test $P>0.05$.

https://doi.org/10.1371/journal.pone.0171379.t003
but lower than those in China (24–64%) [18]. Epidemiological studies have shown no obvious declining incidence of ICH in the past decade in spite of improved control of hypertension, which remains a leading cause of ICH [19–21]. It could be partly explained by the aging population worldwide and the increasing use of antithrombotic medications for preventing ischemic stroke and coronary heart diseases [19, 22].

Although epidemiological studies, clinical studies and meta-analysis have shown that higher cholesterol levels are significantly associated with an elevated risk of coronary heart disease [23–25], the relationship between cholesterol and cerebrovascular disease is complex. While there is evidence relating higher cholesterol levels to significantly increased mortality from ischemic stroke, evidence also shows an inverse relationship between TC levels and hemorrhagic stroke risks [5]. Lower cholesterol levels have been associated with increased mortality from intracranial hemorrhage [26, 27], being more prominently in the elderly [24, 26].

In the present study, ICH patients with baseline TC lower than 160 mg/dL had greater initial stroke severity and higher 3-month mortality. Acute hematoma growth of ICH might explain the early neurological deterioration and mortality, especially for those with lower LDL-C levels [28]. Some studies showed that low LDL-C levels were associated with worse initial severity of ICH patients and with higher in-hospital ICH mortality [4, 29]. Among our ICH patients, 7.8% had past history of ICH, which could be a risk factor for recurrent ICH, with annual recurrent rates from 2.1 to 3.2% [30–32]. ICH recurrence is considered as one of the adverse effects of treatment for hyperlipidemia [33].

Is dyslipidemia per se or intensive lipid-lower treatment related to greater severity and worse outcome of ICH? Prospective studies supported the association between low LDL-C levels and the ICH risk [3, 34]. Wang et al. used a large meta-analysis to demonstrate the inverrd association between lower TC levels and the risk of hemorrhagic stroke [5]. Prospective studies in Japan also showed an elevated risk of ICH mortality in patients with LDL-C <80 mg/dL or TC <160 mg/dL [1, 3]. The interaction of use of statins and TC levels exhibit higher risk towards the ICH [35]. These findings are warning indications that aggressive lipid-lower therapy might be a concern on the ICH risk. Low cholesterol levels resulting from treating patients with cardiovascular diseases and ischemic stroke may increase the ICH risk instead [1].

A meta-analysis including randomized trials, cohort studies and case-control studies failed to find a significant association between statin use and increased ICH [7]. They found a reduced ICH risk in statin users in case-control studies, but the relationship is not significant in cohort studies [7]. However, several meta-analyses only including randomized control studies did show a non-significant excess of hemorrhagic stroke in the groups of statin treatment [1, 36–38]. The similar trends were shown in the groups of randomized placebo-controlled trials of statin and ezetimibe [39, 40]. The ICH risk is not related to the degree of LDL-C reduction or achieved LDL-C [38]. However, an earlier meta-analysis, including 8832 patients with a history of cerebrovascular disease, found a significant increase in the risk of hemorrhagic stroke for statins users despite the reduced risk of ischemic stroke [41]. The level of LDL-C is no longer the treatment goal for hyperlipidemia in high risk patients in the current American College of Cardiology/American Heart Association task force guideline [33]. The effect of prior statin use in our study was consistent with other studies, neither associated with TC levels at presentation, nor with worse initial severity [42] and 3-month mortality in other studies [4, 43, 44]. Pre-ICH use of lipid-lowering drugs in small percentage of the ICH population (2.8%) was not associated with initial severity and 3-month outcomes, but prior use of statins were associated with better initial Glasgow Coma Scale score [4], and 3-month functional outcome in one study [9] but not in another [43].

Several studies have shown an increased ICH risk in extremely low or high BMI [45–47]. The present study demonstrated that the impact of low cholesterol on ICH severity and a
worse prognosis was even more significant in patients with low BMI. BMI < 22.0 kg/m² was associated with 1.8-fold increase in the presenting ICH severity and nearly 4-fold increase in 3-month mortality. An eight-year hypertension follow-up study in China showed that either low or high BMI was associated with an increased risk in deep ICH, but not in lobar ICH [46]. A multi-center Italian case-control study found that obesity was associated with an increased risk of deep ICH indirectly through hypertension and diabetes mellitus, but without major effect on the risk of lobar ICH [48].

This study shows that a lower cholesterol level at the presentation of ICH is associated with worse initial severity and 3-months mortality, especially for those with a low BMI, but not with prior lipid-lower medication. A total cholesterol level lower than 160 mg/dL might be a concern in treating patients with dyslipidemia and high risk of intracerebral hemorrhage. For further verifying the conclusion, we performed further data analysis by establishing propensity score matched study groups and showed approximately similar findings. However, there are limitations to this study. First, the impact of high-density and low-density cholesterol was not investigated in the study. Second, cholesterol levels may vary overtime in the acute stage of stroke, although the difference was not significant in cerebral hemorrhage [49]. Third, the specific types of pre-ICH lipid-lowering drugs were not recorded in the registry and the percentage of pre-ICH lipid-lowering drug use was too small to have a solid conclusion of its impact on the ICH outcome. Fourth, fasting cholesterol levels were not measured in a large portion of ICH patients, and therefore the analysis might be weakened (S1 Table).

Supporting information

S1 Table. Characteristics of patients with intracerebral hemorrhage by total cholesterol levels on admission. Values are presented as mean ± standard deviation, number (percentage) or median (interquartile rang). TIA: transient ischemic attack, ICH: intracerebral hemorrhage; NIHSS: National Institute of Health and Stroke Scale. Chi-square test, †t-test and ‡Wilcoxon rank-sum test.

Acknowledgments

We are grateful to Taiwan Stroke Registry Investigators for their assistance with data collected and management from each hospital.

List of TSR investigators

China Medical University Hospital: Chung-Hsiang Liu\textsuperscript{d} (Principal Investigator), Chon-Haw Tsai, Wei-Shih Huang, Chung-Ta Lu, Tzung-Chang Tsai, Chun-Hung Tseng, Kang-Hsu Lin, Woei-Cherng Shyu, Yu-Wan Yang, Yen-Liang Liu, Der-Yang Cho, Chun-Chung Chen

National Taiwan University Hospital: Jiann-Shing Jeng\textsuperscript{r} (Principal Investigator), Sung-Chun Tang, Li-Kai Tsai, Shin-Joe Yeh

E-Da Hospital / I-Shou University: Shih-Pin Hsu\textsuperscript{n} (Principal Investigator), Han-Jung Chen, Cheng-Sen Chang, Hung-Chang Kuo, Lian-Hui Lee, Huan-Wen Tsui, Jung-Chi Tsou, Yan-Tang Wang, Yi-Cheng Tai, Kun-Chan Tsai, Yen-Wen Chen, Kan Lu, Po-Chao Liliang, Yu-Tun Tsai, Cheng-Loong Liang, Kuo-Wei Wang, Hao-Kuang Wang, Jui-Sheng Chen, Po-Yuan Chen, Cien-Leong Chye, Wei-Jie Tzeng, Pei-Hua Wu

National Cheng Kung University Hospital: Chih-Hung Chen\textsuperscript{e} (Principal Investigator), Pi-Shan Sung, Han-Chieh Hsieh, Hui-Chen Su
Shin Kong WHS Memorial Hospital: Hou-Chang Chiu (Principal Investigator), Li-Ming Lien, Wei-Hung Chen, Chyi-Huey Bai, Tzu-Hsuan Huang, Chi-Leong Lau, Ya-Ying Wu, Hsu-Ling Yeh, Anna Chang

Kaohsiung Veterans General Hospital: Ching-Huang Lin<sup>a</sup> (Principal Investigator), Cheng-Chang Yen

Kaohsiung Medical University Chung-Ho Memorial Hospital: Ruey-Tay Lin (Principal Investigator), Chun-Hung Chen, Gim-Thean Khor, A-Ching Chao, Hsiu-Fen Lin, Poyin Huang

Chia Mei Medical Center: Huey-Juan Lin (Principal Investigator), Der-Shin Ke, Chia-Yu Chang, Poh-Shiow Yeh, Kao-Chang Lin, Tain-Junn Cheng, Chih-Ho Chou, Chun-Ming Yang, Hsiu-Chu Shen

Chung Shan Medical University Hospital: An-Chih Chen<sup>b</sup> (Principal Investigator), Shih-Jei Tsai, Tsong-Ming Lu, Sheng-Ling Kuang, Mei-Ju Lee, Hsi-Hsien Chou

Show Chwan Memorial Hospital: Hsin-Yi Chi (Principal Investigator), Chou-Hsiung Pan, Po-Chi Chan, Min-Hsien Hsu, Wei-Lun Chang, Ya-Ying Wu, Zhi-Zang Huang, Hai-Ming Shoung, Yi-Chen Lo, Fu-Hwa Wang

Cheng Hsin General Hospital: Ta-Chang Lai (Principal Investigator), Jiu-Haw Yin, Chung-Jen Wang, Kai-Chen Wang, Li-Mei Chen, Jong-Chyou Denq

En Chu Kong Hospital: Yu Sun (Principal Investigator), Chien-Jung Lu, Cheng-Huai Lin, Chieh-Cheng Huang, Chang-Hsiu Liu, Hoi-Fong Chan

Far Eastern Memorial Hospital: Siu-Pak Lee (Principal Investigator)

Kuang Tien General Hospital: Ming-Hui Sun (Principal Investigator), Li-Ying Ke

Taichung Veterans General Hospital: Po-Lin Chen<sup>c</sup> (Principal Investigator), Yu-Shan Lee

Ditmanson Medical Foundation Chia-Yi Christian Hospital: Sheng-Feng Sung<sup>d</sup> (Principal Investigator), Cheung-Ter Ong, Chi-Shun Wu, Yu-Hsiang Su, Ling-Chien Hung

Tri-Service General Hospital: Jiuann-Tay Lee (Principal Investigator), Jiann-Chyun Lin, Yaw-Don Hsu, Jong-Chyou Denq, Giia-Sheun Peng, Chang-Hung Hsu, Chun-Chieh Lin, Che-Hung Yen, Chun-An Cheng, Yueh-Feng Sung, Yuan-Liang Chen, Ming-Tung Lien, Chung-Hsing Chou, Chia-Chen Liu, Fu-Chi Yang, Yi-Chung Wu, An-Chen Tso, Yu-Hua Li, Chun-I Chiang, Chia-Kuang Tsai, Meng-Ta Liu, Ying-Che Lin, Yu-Chuan Hsu

Cathay General Hospital: Tsuey-Ru Chiang (Principal Investigator), Mei-Ching Lee, Pai-Hao Huang, Sian-King Lie, Pin-Wen Liao, Jen-Tse Chen

Changhua Christian Hospital: Mu-Chien Sun (Principal Investigator), Tien-Pao Lai, Wei-Liang Chen, Yen-Chun Chen, Ta-Cheng Chen, Wen-Fu Wang, Kwo-Whei Lee, Chen-Shu Chang, Chien-Hsu Lai, Siao-Ya Shih, Chieh-Sen Chuang, Yen-Yu Chen, Chien-Min Chen

Taipei Tzuchi Hospital, Buddhist Tzuchi Medical Foundation:

Shinn-Kuang Lin<sup>e</sup> (Principal Investigator), Yu-Chin Su, Cheng-Lun Hsiao, Fu-Yi Yang, Chih-Yang Liu, Han-Lin Chiang, Ser-Chen Fu

Min Sheng General Hospital: Chun-Yuan Chang (Principal Investigator), I-Sheng Lin, Chung-Hsien Chien, Yang-Chuang Chang

Lin Shin Hospital: Ping-Kun Chen<sup>f</sup> (Principal Investigator), Pai-Yi Chiu

National Taiwan University Hospital Yunlin Branch: Yu-Jen Hsiao<sup>g</sup> (Principal Investigator), Chen-Wen Fang

Taiwan Landseed Hospital: Yu-Wei Chen<sup>h</sup> (Principal Investigator), Kuo-Ying Lee, Yun-Yu Lin, Chen-Hua Li<sup>i</sup>, Hui-Fen Tsai, Chuan-Fa Hsieh, Chih-Dong Yang<sup>j</sup>, Shiumn-Jen Liaw, How-Chin Liao
Cheng Ching General Hospital: Shoou-Jeng Yeh (Principal Investigator), Ling-Li Wu, Liang-Po Hsieh, Yong-Hui Lee, Chung-Wen Chen
China Medical University Beigang Hospital: Chih- Shan Hsu (Principal Investigator), Ye-Jian Jih, Hao-Yu Zhuang, Yan-Hong Pan, Shin-An Shih
Taipei Medical University -Wan Fang Hospital: Chin-I Chen (Principal Investigator), Jia-Ying Sung, Hsing-Yu Weng, Hao-Wen Teng, Jing-Er Lee, Chih-Shan Huang, Shu-Ping Chao
Taipei Medical University Hospital: Rey-Yue Yuan (Principal Investigator), Jau-Juan Sheu, Jia-Ming Yu, Chun-Sum Ho, Ting-Chun Lin
Kuang Tien General Hospital Dajia Division: Shih-Chieh Yu (Principal Investigator), Song-Yen Tsai
Chang Bing Show Chwan Memorial Hospital: Cheng-Yu Wei (Principal Investigator), Tzu-Hsuan Huang, Chao-Nan Yang, Chao-Hsien Hung, Ian Shih
Lotung Poh Ai Hospital: Hung-Pin Tseng (Principal Investigator), Chin-Hsiung Liu, Chun-Liang Lin, Hung-Chih Lin, Pi-Tzu Chen
Taipei Medical University—Shuang Ho Hospital: Chaur-Jong Hu (Principal Investigator), Nai-Fang Chi, Lung Chan
Taipei Veterans General Hospital & National Yang-Ming University School of Medicine: Chang-Ming Chern (Principal Investigator), Chu- Jen Lin, Shuu-Jiun Wang, Li-Chi Hsu, Wen-Jang Wong, I-Hui Lee, Der-Jen Yen, Ching-Piao Tsai, Shang-Yeong Kwan, Bing-Wen Soong, Shih-Pin Chen, Kwong-Kum Liao, Kung-Ping Lin, Chien Chen, Din-E Shan, Jong-Ling Fuh, Pei-Ning Wang, Yi-Chung Lee, Yu-Hsiang Yu, Hui-Chi Huang, Jui-Yao Tsai
Chi Mei Medical Center, Liouying: Ming-Hsiu Wu (Principal Investigator), Shi-Cheng Chen, Szu-Yi Chiang, Chiung-Yao Wang
Buddhist Dalin Tzu Chi General Hospital: Ming-Chin Hsu (Principal Investigator)
St. Martin De Porres Hospital: Chien-Chung Chen (Principal Investigator), Po-Yen Yeh, Yu-Tai Tsai, Ko-Yi Wang
Sin-Lau Hospital, Tainan, the Presbyterian Church in Taiwan: Tsang-Shan Chen (Principal Investigator)
Cardinal Tien Hospital: Ping-Keung Yip (Principal Investigator), Vinchi Wang, Kay-Chen Wang, Chung-Fen Tsai, Chao-Ching Chen, Chih-Hao Chen, Yi-Chien Liu, Shao-Yuan Chen, Zi-Hao Zhao, Zhi-Peng Wei
Yumin Medical Corporation Yumin Hospital: Shey-Lin Wu (Principal Investigator)
Kaohsiung Municipal Hsiao-kang Hospital: Ching-Kuan Liu (Principal Investigator)
Wei Gong Memorial Hospital: Ryh-Huei Lin (Principal Investigator), Ching-Hua Chu
Taipei City Hospital Ren Ai Branch: Sui-Hing Yan (Principal Investigator), Yi-Chun Lin, Pei-Yun Chen, Sheng-Huang Hsiao
National Taiwan University Hospital Hsin-Chu Branch: Bak-Sau Yip (Principal Investigator), Pei-Chun Tsai, Ping-Chen Chou, Tsam-Ming Kuo, Yi-Chen Lee, Yi-Pin Chiu, Kun-Chang Tsai
Taichung Hospital Department of Health: Yi-Sheng Liao (Principal Investigator)
Tainan Municipal An-Nan Hospital-China Medical University: Ming-Jun Tsai (Principal Investigator), Hsin-Yi Kao

Author Contributions

Conceptualization: YWC C. H. Li CDY C. H. Lin CHC JJS SKL ACC PKC PLC CHY JRC YJH C. H. Liu SPH TSC SFS SCY CHM CPW FCS JSJ CYH.

Data curation: YWC CHM FCS JSJ CYH.
Formal analysis: YWC CHM FCS JSJ CYH.

Funding acquisition: CYH.

Investigation: YWC C. H. Li CDY C. H. Lin CHC JJS SKL ACC PKC PLC CHY JRC YJH C. H. Liu SPH TSC SFS SCY CHM CPW FCS JSJ CYH.

Methodology: YWC C. H. Li CHC JJS SKL ACC PKC PLC CHY JRC YJH C. H. Liu SPH TSC SFS SCY CHM CPW FCS JSJ CYH.

Project administration: JSJ CYH.

Resources: YWC C. H. Li CDY C. H. Lin CHC JJS SKL ACC PKC PLC CHY JRC YJH C. H. Liu SPH TSC SFS SCY CHM CPW FCS JSJ CYH.

Software: YWC CHM FCS JSJ CYH.

Supervision: FCS JSJ CYH.

Validation: YWC CHM FCS JSJ CYH.

Visualization: YWC CHM FCS JSJ.

Writing – original draft: YWC C. H. Li CHM FCS JSJ CYH.

Writing – review & editing: YWC FCS JSJ CYH.

References

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670–81. https://doi.org/10.1016/S0140-6736(10)61350-5 PMID: 21067804

2. Woo D, Kissela BM, Khoury JC, Sauerbeck LR, Haverbusch MA, Szafirski JP, et al. Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study. Stroke. 2004; 35:1960–4. https://doi.org/10.1161/01.STR.0000127786.16612.A4 PMID: 15087556

3. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Doi M, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation. 2009; 119:2136–45. https://doi.org/10.1161/CIRCULATIONAHA.108.796666 PMID: 19364982

4. Mustanoja S, Strbian D, Putaala J, Meretoja A, Curtze S, Haapaniemi E, et al. Association of prestroke statin use and lipid levels with outcome of intracerebral hemorrhage. Stroke. 2013; 44:2330–2. https://doi.org/10.1161/STROKEAHA.113.001829 PMID: 23760210

5. Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke. 2013; 44:1833–9. https://doi.org/10.1161/STROKEAHA.113.001326 PMID: 23704101

6. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008; 70:2364–70. https://doi.org/10.1212/01.wnl.0000296277.63950.77 PMID: 18077795

7. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011; 124:2233–42. https://doi.org/10.1161/CIRCULATIONAHA.111.065269 PMID: 22007076

8. Wang W, Zhang B. Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. PLoS One. 2014; 9:e89238. PubMed Central PMCID: PMCPMC3958535. https://doi.org/10.1371/journal.pone.0092388 PMID: 24643199

9. Biffi A, Devan WJ, Anderson CD, Ayres AM, Schwab K, Cortellini L, et al. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology. 2011; 76:1581–6. https://doi.org/10.1212/WNL.0b013e3182194ba9 PMID: 21451150

10. Dowlatshahi D, Demchuk AM, Fang J, Kapral MK, Sharma M, Smith EE. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke. 2012;431518–23.

11. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, et al. Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-
12. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97:1837–47. PMID: 9603539

13. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285:2370–5. PMID: 11343485

14. Brott T, Adams HP Jr., Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989; 20:864–70. PMID: 2749846

15. Schlegel D, Kolb SJ, Luciano JM, Tovar JM, Cucchiara BL, Liebeskind DS, et al. Utility of the NIH Stroke Scale as a predictor of hospital disposition. Stroke. 2003; 34:134–7. PMID: 12511764

16. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009; 373:1632–44. https://doi.org/10.1016/S0140-6736(09)60371-8 PMID: 19427958

17. Kiyohara Y, Kubo M, Kato I, Tanizaki Y, Tanaka K, Okubo K, et al. Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study. Stroke. 2003; 34:2343–7. https://doi.org/10.1212/01.wnl.0000180968.26242.4a PMID: 14500930

18. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol. 2007; 6:456–64. https://doi.org/10.1016/S1474-4422(07)7004-2 PMID: 17434100

19. Lovelock CE, Molyneux AJ, Rothwell PM. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol. 2007; 6:487–93. https://doi.org/10.1016/S1474-4422(07)70107-2 PMID: 17509483

20. Kita Y, Turin TC, Ichikawa M, Sugihara H, Morita Y, Tomioka N, et al. Trend of stroke incidence in a Japanese population: Takashima stroke registry, 1990–2001. Int J Stroke. 2009; 4:241–9. https://doi.org/10.1111/1747-4949.2009.00293.x PMID: 19689749

21. Benatru I, Rouaud O, Durier J, Conteogel F, Couvreur G, Bejot Y, et al. Stable stroke incidence rates but improved case-fatality in Dijon, France, from 1985 to 2004. Stroke. 2006; 37:1674–9. https://doi.org/10.1161/01.STR.0000226977.56456.a8 PMID: 16728682

22. Flaherty ML, Kissela B, Woo D, Kleinodfer D, Alwell K, Sekar P, et al. The increasing incidence of anti-coagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116–21. https://doi.org/10.1212/01.wnl.0000250340.05202.8b PMID: 17210891

23. Castell WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med. 1984; 76:4–12. PMID: 6702862

24. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370:1929–39. https://doi.org/10.1016/S0140-6736(07)61778-4 PMID: 17509483

25. Woo D, Deka R, Falcone GJ, Flaherty ML, Haverbusch M, Martini SR, et al. Apolipoprotein e, statins, and risk of intracerebral hemorrhage. Stroke. 2013; 44:3013–7. https://doi.org/10.1161/STROKEAHA.112.0000134 PMID: 23008570

26. Iso H, Jacobs DR Jr., Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. New Engl J Med. 1989; 320:904–10. https://doi.org/10.1056/NEJM198904063201405 PMID: 2619783

27. Ramirez-Moreno JM, Casado-Naranjo I, Portilla JC, Calle ML, Tena D, Falcon A, et al. Serum cholesterol LDL and 90-day mortality in patients with intracerebral hemorrhage. Stroke. 2009; 40:1917–20. https://doi.org/10.1161/01.STR.0000226977.56456.a8 PMID: 19689749

28. Rodriguez-Luna D, Rubiera M, Ribo M, Coscojuela P, Pagola J, Pineiro S, et al. Serum low-density lipoprotein cholesterol level predicts hematoma growth and clinical outcome after acute intracerebral hemorrhage. Stroke. 2011; 42:2447–52. https://doi.org/10.1161/STROKEAHA.110.609461 PMID: 21799167

29. Roquer J, Rodriguez-Campello A, Gosina M, Ois A, Munteis E, Bohm P. Serum lipid levels and in-hospital mortality in patients with intracerebral hemorrhage. Neurology. 2005; 65:1198–202. https://doi.org/10.1212/01.wnl.0000180968.26242.4a PMID: 16247046

30. Zia E, Engstrom G, Svensson PJ, Norrving B, Pessah-Rasmussen H. Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke. 2009; 40:3567–73. https://doi.org/10.1161/STROKEAHA.109.556324 PMID: 19729603

31. Yeh SJ, Tang SC, Tsai LK, Jeng JS. Pathogenetical subtypes of recurrent intracerebral hemorrhage: designations by SMASH-U classification system. Stroke. 2014; 45:2636–42. https://doi.org/10.1161/STROKEAHA.114.005598 PMID: 25052320
32. Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 2007; 78:836–40. https://doi.org/10.1136/jnnp.2006.106500 PMID: 17220294

33. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2):S1–45. https://doi.org/10.1161/CIR.00000437738.63853.7a PMID: 24222016

34. Sturgeon JD, Folsom AR, Longstreth WT Jr., Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke. 2007; 38:2718–25. https://doi.org/10.1161/STROKEAHA.107.487090 PMID: 17761915

35. Pezzini A, Grassi M, Iacoviello L, Zedde M, Marcheselli S, Silvestrelli G, et al. Serum cholesterol levels, HMG-CoA reductase inhibitors and the risk of intracerebral haemorrhage. The Multicenter Study on Cerebral Haemorrhage in Italy (MUCH-Italy). J Neurol Neurosurg Psychiatry. 2016; 87:924–9. https://doi.org/10.1136/jnnp-2015-312736 PMID: 27003275

36. Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy: a meta-analysis of individual data from 90,056 participants in 14 randomised trials of statins. Lancet. 2012; 380:581–90. https://doi.org/10.1016/S0140-6736(12)60367-5 PMID: 22607822

37. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012; 43:2149–56. https://doi.org/10.1161/STROKEAHA.112.655894 PMID: 22588266

38. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Theroux P, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377:2181–92. https://doi.org/10.1016/S0140-6736(11)60739-3 PMID: 21663949

39. Bleicker R, Khoury ST, Ben-Hur T, Keidar M, Paniri R, Leker RR. Prior use of statins and outcome in patients with intracerebral haemorrhage. Eur J Neurol. 2010; 17:78–83. https://doi.org/10.1111/j.1468-1331.2009.02747.x PMID: 19614959

40. Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke: a prospective study in Korean men. Stroke. 2004; 35:831–6. https://doi.org/10.1161/01.STR.0000119386.22691.1C PMID: 15001798

41. Bazzano LA, Gu D, Whelton MR, Wu X, Chen CS, Duan X, et al. Body mass index and risk of stroke among Chinese men and women. Ann Neurol. 2010; 67:11–20. https://doi.org/10.1002/ana.21950 PMID: 20186847

42. Biffi A, Cortellini L, Nearnberg CM, Ayres AM, Schwab K, Chanderraj R, Kinnecon C, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke. 2008; 39:2151–4. https://doi.org/10.1161/STROKEAHA.107.508861 PMID: 18436876

43. Eichel R, Khoury ST, Ben-Hur T, Keidar M, Paniri R, Leker RR. Prior use of statins and outcome in patients with intracerebral haemorrhage. Eur J Neurol. 2010; 17:78–83. https://doi.org/10.1111/j.1468-1331.2009.02747.x PMID: 19614959

44. Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke: a prospective study in Korean men. Stroke. 2004; 35:831–6. https://doi.org/10.1161/01.STR.0000119386.22691.1C PMID: 15001798

45. Bazzano LA, Gu D, Whelton MR, Wu X, Chen CS, Duan X, et al. Body mass index and risk of stroke among Chinese men and women. Ann Neurol. 2010; 67:11–20. https://doi.org/10.1002/ana.21950 PMID: 20186847

46. Biffi A, Cortellini L, Nearnberg CM, Ayres AM, Schwab K, Chanderraj R, Kinnecon C, et al. Effect of statins on intracerebral hemorrhage outcome and recurrence. Stroke. 2008; 39:2151–4. https://doi.org/10.1161/STROKEAHA.107.508861 PMID: 18436876

47. Eichel R, Khoury ST, Ben-Hur T, Keidar M, Paniri R, Leker RR. Prior use of statins and outcome in patients with intracerebral haemorrhage. Eur J Neurol. 2010; 17:78–83. https://doi.org/10.1111/j.1468-1331.2009.02747.x PMID: 19614959

48. Song YM, Sung J, Davey Smith G, Ebrahim S. Body mass index and ischemic and hemorrhagic stroke: a prospective study in Korean men. Stroke. 2004; 35:831–6. https://doi.org/10.1161/01.STR.0000119386.22691.1C PMID: 15001798

49. Bazzano LA, Gu D, Whelton MR, Wu X, Chen CS, Duan X, et al. Body mass index and risk of stroke among Chinese men and women. Ann Neurol. 2010; 67:11–20. https://doi.org/10.1002/ana.21950 PMID: 20186847